Aggressive Cut Stack

The Aggressive Cut Stack is a high-potency fat loss protocol designed for experienced peptide users seeking rapid and sustained body recomposition. This advanced stack combines three powerful compounds that target adipose tissue through complementary metabolic pathways, creating a synergistic effect far greater than any single agent alone. Semaglutide, a GLP-1 receptor agonist administered at 500mcg weekly, dramatically reduces appetite and improves insulin sensitivity by mimicking the incretin hormone system. It slows gastric emptying and acts on hypothalamic hunger centers, making caloric restriction feel effortless rather than punishing. Research published in the New England Journal of Medicine has demonstrated significant reductions in body weight with sustained GLP-1 agonist therapy. Tesamorelin at 2000mcg daily specifically targets visceral adipose tissue—the metabolically dangerous fat surrounding internal organs. Originally developed for HIV-associated lipodystrophy, tesamorelin stimulates growth hormone releasing hormone (GHRH) receptors, promoting lipolysis while preserving lean muscle mass. Clinical trials have shown meaningful reductions in trunk fat without the side effects associated with exogenous GH administration. AOD-9604, dosed at 500mcg daily, is a modified fragment of human growth hormone (amino acids 177-191) that stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or growth. It activates beta-3 adrenergic receptors in fat tissue, accelerating fatty acid oxidation. Protocol Notes: Semaglutide should be titrated slowly over 4-6 weeks to minimize gastrointestinal side effects. Tesamorelin and AOD-9604 are best administered on an empty stomach, ideally in the morning before food. This stack is suited for individuals who have already optimized diet and training, have prior peptide experience, and are looking to break through stubborn fat loss plateaus. Cycle duration is typically 12-16 weeks with bloodwork monitoring recommended at baseline and mid-cycle.